Valuation : Delcath Systems, Inc.

Market Cap 56Cr 48Cr 45Cr 41Cr 77Cr 5.31TCr 77Cr 535.79Cr 207.08Cr 2.7TCr 209.51Cr 204.96Cr 8.57TCr P/E 2026 *
-107x
P/E 2027 * -201x
Enterprise Value 56Cr 48Cr 45Cr 41Cr 77Cr 5.31TCr 77Cr 535.79Cr 207.08Cr 2.7TCr 209.51Cr 204.96Cr 8.57TCr EV / Sales 2026 *
5.25x
EV / Sales 2027 * 4.23x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/10/2020
Director of Finance/CFO 47 01/05/2023
Chief Operating Officer 55 18/03/2024
Director TitleAgeSince
Chairman 62 16/02/2023
Director/Board Member 70 14/02/2020
Director/Board Member 60 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%-3.26%-0.49%-27.20% 1.84TCr
-1.64%-4.13%-5.72%+4.74% 1.7TCr
-3.11%+0.71%-54.88%-49.75% 659.56Cr
-1.05%-3.57% - - 427.2Cr
+1.42%+0.05%+33.91%+72.00% 206.61Cr
-2.11%-4.13%-11.02%-7.48% 188.29Cr
-2.41%-2.92%-52.33%-56.58% 116Cr
+0.06%-3.11%+38.49%+227.86% 56Cr
-0.49%-1.29% - - 30Cr
Average -1.13%-0.75%-7.43%+23.37% 580.66Cr
Weighted average by Cap. -1.47%-1.70%-9.61%-11.60%

Financials

2026 *2027 *
Net sales 11Cr 9.14Cr 8.61Cr 7.84Cr 15Cr 1.01TCr 15Cr 101.99Cr 39Cr 514.88Cr 40Cr 39Cr 1.63TCr 13Cr 11Cr 11Cr 9.74Cr 18Cr 1.26TCr 18Cr 126.74Cr 49Cr 639.82Cr 50Cr 48Cr 2.03TCr
Net income -57.21L -49.23L -46.36L -42.24L -79.03L -54Cr -79.34L -5.49Cr -2.12Cr -28Cr -2.15Cr -2.1Cr -88Cr -33.88L -29.15L -27.45L -25.01L -46.8L -32Cr -46.98L -3.25Cr -1.26Cr -16Cr -1.27Cr -1.24Cr -52Cr
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!